NCT04737304 - A First-in-Human PoC Study With BEN2293 in Patients With Mild to Moderate Atopic Dermatitis | Biotech Hunter

Enrollment

123

Participants

Timeline

Start Date

October 14, 2020

Primary Completion Date

January 12, 2023

Study Completion Date

January 26, 2023

Conditions

Atopic Dermatitis

Interventions

DRUG

BEN2293 (0.25% or 1.0% w/w) or matching placebo

BEN2293 and placebo will be administered as a topical ointment. Both ointments contain the same excipients; placebo ointment has been manufactured in the same way except for the addition of 0.25% and 1.0% (w/w) BEN2293.

Trial Locations (1)

M13 9NQ

MAC Clinical Research, Manchester